NAMS MENOPAUSE CERTIFICATION EXAM (2025/2026)
Actual Real Exam Test Bank | 2 Currently Testing Versions | 100 Questions Each | Expert
Verified | Guaranteed Pass
Overview
This 2025/2026 validated resource contains the complete NAMS Menopause
Certification exam bank with 2 currently testing versions (100 questions each) and
expert-verified answers with rationales. Essential for healthcare providers seeking North
American Menopause Society certification and demonstrating mastery in menopause and
midlife women's health.
Key Features
✓ 200 Total Questions (2 versions, 100 questions each)
✓ Currently testing exam content from recent administrations
✓ Comprehensive study guide with high-yield focus areas
✓ Updated 2025/2026 NAMS guidelines and position statements
✓ Guaranteed pass assurance with performance analytics
Exam Versions Content
● Version A: Comprehensive Menopause Management (100 Questions)
● Version B: Advanced Clinical Applications (100 Questions)
Core Content Areas
● Hormone Therapy & Pharmacology (40 Questions)
● Non-Hormonal Management Strategies (35 Questions)
● Midlife Health & Chronic Disease Prevention (35 Questions)
● Comprehensive Assessment & Diagnosis (30 Questions)
● Special Populations & Complex Cases (30 Questions)
● Patient Education & Shared Decision-Making (30 Questions)
Answer Format
Verified correct answers in bold green with:
● Current NAMS guideline citations
● Evidence-based practice rationales
● Clinical application scenarios
● Risk-benefit analysis frameworks
🔹
Critical Updates 2025/2026
🔹
CURRENTLY TESTING - 2025 Hormone Therapy Position Statement
🔹
NEWLY ADDED - Genitourinary Syndrome of Menopause (GSM) protocols
🔹
HEAVILY TESTED - Breast cancer risk assessment and management
UPDATED - Osteoporosis prevention and treatment guidelines
,Study Guide Includes
✓ High-yield topic review sheets
✓ Clinical decision-making algorithms
✓ Patient counseling templates
✓ Quick-reference medication charts
Footer
NAMS Menopause Certification Exam | 2025/2026 Edition | 200 Questions | 2 Testing Versions
| Not Affiliated with NAMS
Version A: Comprehensive Menopause Management
(100 Questions)
Section 1: Hormone Therapy & Pharmacology (Questions 1–40)
1. What is the primary indication for estrogen therapy in postmenopausal
women?
a) Breast cancer prevention
b) Symptom relief of vasomotor symptoms
c) Osteoporosis treatment
d) All of the above
b) Symptom relief of vasomotor symptoms
Rationale: Estrogen therapy is primarily indicated for vasomotor symptoms (hot flashes, night
sweats) in postmenopausal women, per the 2025 NAMS Hormone Therapy Position Statement.
It is not first-line for cancer prevention or osteoporosis without specific indications._
2. Which route of estrogen administration has the lowest risk of venous
thromboembolism?
a) Oral
b) Transdermal
c) Vaginal
d) Intramuscular
b) Transdermal
Rationale: Transdermal estrogen avoids first-pass hepatic metabolism, reducing clotting risk
compared to oral routes (NAMS, 2025)._
3. What is the recommended duration of hormone therapy for women with
no contraindications?
a) 1 year maximum
b) Individualized, based on benefits vs. risks
c) 5 years maximum
d) Lifetime use
b) Individualized, based on benefits vs. risks
,Rationale: NAMS recommends individualized HT duration, balancing symptom relief and risks,
with no arbitrary time limit (NAMS, 2025)._
4. Which progestogen is preferred for continuous combined HT in women
with a uterus?
a) Micronized progesterone
b) Medroxyprogesterone acetate
c) Norethindrone
d) Levonorgestrel
a) Micronized progesterone
Rationale: Micronized progesterone has a more favorable cardiovascular risk profile than
synthetic progestins (NAMS, 2025)._
5. What is the absolute contraindication for hormone therapy?
a) Age over 60
b) History of breast cancer
c) Hot flashes
d) Vaginal dryness
b) History of breast cancer
Rationale: HT is contraindicated in breast cancer survivors due to increased recurrence risk
(NAMS, 2025)._
6. Which estrogen formulation is recommended for genitourinary
syndrome of menopause?
a) Oral conjugated estrogens
b) Low-dose vaginal estrogen
c) Transdermal estradiol
d) High-dose estrogen patch
b) Low-dose vaginal estrogen
Rationale: Low-dose vaginal estrogen is first-line for GSM, with minimal systemic absorption
(NAMS GSM Protocol, 2025)._
7. What is the primary risk of hormone therapy in women over age 60?
a) Venous thromboembolism
b) Stroke
c) Breast cancer
d) All of the above
d) All of the above
Rationale: HT in older women increases risks of VTE, stroke, and breast cancer, requiring
individualized assessment (NAMS, 2025)._
8. Which non-hormonal therapy is recommended for vasomotor
symptoms?
a) Paroxetine
b) Gabapentin
c) Both a and b
, d) Neither a nor b
c) Both a and b
Rationale: SSRIs like paroxetine and gabapentinoids like gabapentin are effective
non-hormonal options for hot flashes (NAMS, 2025)._
9. What is the recommended screening for breast cancer in women on HT?
a) Annual mammogram
b) Biennial mammogram
c) No screening needed
d) Monthly self-exam only
a) Annual mammogram
Rationale: Women on HT require annual mammograms for breast cancer screening, starting at
age 40 or earlier if high risk (USPSTF, 2025)._
10. Which hormone therapy regimen is recommended for a woman with a
uterus?
a) Estrogen only
b) Estrogen plus progestogen
c) Progestogen only
d) No hormone therapy
b) Estrogen plus progestogen
Rationale: Combined estrogen-progestogen therapy is required in women with an intact uterus
to prevent endometrial hyperplasia (NAMS, 2025)._
11. What is the primary benefit of transdermal hormone therapy?
a) Lower cost
b) Reduced first-pass liver metabolism
c) Easier administration
d) Longer duration of action
b) Reduced first-pass liver metabolism
Rationale: Transdermal HT bypasses first-pass metabolism, lowering VTE risk (NAMS, 2025)._
12. Which symptom is most indicative of genitourinary syndrome of
menopause?
a) Hot flashes
b) Vaginal dryness
c) Mood swings
d) Weight gain
b) Vaginal dryness
Rationale: GSM is characterized by vaginal dryness, dyspareunia, and urinary symptoms due to
estrogen deficiency (NAMS GSM Protocol, 2025)._
13. What is the recommended starting dose for estradiol vaginal ring?
a) 0.05 mg/day
b) 0.1 mg/day
c) 0.3 mg/day
Actual Real Exam Test Bank | 2 Currently Testing Versions | 100 Questions Each | Expert
Verified | Guaranteed Pass
Overview
This 2025/2026 validated resource contains the complete NAMS Menopause
Certification exam bank with 2 currently testing versions (100 questions each) and
expert-verified answers with rationales. Essential for healthcare providers seeking North
American Menopause Society certification and demonstrating mastery in menopause and
midlife women's health.
Key Features
✓ 200 Total Questions (2 versions, 100 questions each)
✓ Currently testing exam content from recent administrations
✓ Comprehensive study guide with high-yield focus areas
✓ Updated 2025/2026 NAMS guidelines and position statements
✓ Guaranteed pass assurance with performance analytics
Exam Versions Content
● Version A: Comprehensive Menopause Management (100 Questions)
● Version B: Advanced Clinical Applications (100 Questions)
Core Content Areas
● Hormone Therapy & Pharmacology (40 Questions)
● Non-Hormonal Management Strategies (35 Questions)
● Midlife Health & Chronic Disease Prevention (35 Questions)
● Comprehensive Assessment & Diagnosis (30 Questions)
● Special Populations & Complex Cases (30 Questions)
● Patient Education & Shared Decision-Making (30 Questions)
Answer Format
Verified correct answers in bold green with:
● Current NAMS guideline citations
● Evidence-based practice rationales
● Clinical application scenarios
● Risk-benefit analysis frameworks
🔹
Critical Updates 2025/2026
🔹
CURRENTLY TESTING - 2025 Hormone Therapy Position Statement
🔹
NEWLY ADDED - Genitourinary Syndrome of Menopause (GSM) protocols
🔹
HEAVILY TESTED - Breast cancer risk assessment and management
UPDATED - Osteoporosis prevention and treatment guidelines
,Study Guide Includes
✓ High-yield topic review sheets
✓ Clinical decision-making algorithms
✓ Patient counseling templates
✓ Quick-reference medication charts
Footer
NAMS Menopause Certification Exam | 2025/2026 Edition | 200 Questions | 2 Testing Versions
| Not Affiliated with NAMS
Version A: Comprehensive Menopause Management
(100 Questions)
Section 1: Hormone Therapy & Pharmacology (Questions 1–40)
1. What is the primary indication for estrogen therapy in postmenopausal
women?
a) Breast cancer prevention
b) Symptom relief of vasomotor symptoms
c) Osteoporosis treatment
d) All of the above
b) Symptom relief of vasomotor symptoms
Rationale: Estrogen therapy is primarily indicated for vasomotor symptoms (hot flashes, night
sweats) in postmenopausal women, per the 2025 NAMS Hormone Therapy Position Statement.
It is not first-line for cancer prevention or osteoporosis without specific indications._
2. Which route of estrogen administration has the lowest risk of venous
thromboembolism?
a) Oral
b) Transdermal
c) Vaginal
d) Intramuscular
b) Transdermal
Rationale: Transdermal estrogen avoids first-pass hepatic metabolism, reducing clotting risk
compared to oral routes (NAMS, 2025)._
3. What is the recommended duration of hormone therapy for women with
no contraindications?
a) 1 year maximum
b) Individualized, based on benefits vs. risks
c) 5 years maximum
d) Lifetime use
b) Individualized, based on benefits vs. risks
,Rationale: NAMS recommends individualized HT duration, balancing symptom relief and risks,
with no arbitrary time limit (NAMS, 2025)._
4. Which progestogen is preferred for continuous combined HT in women
with a uterus?
a) Micronized progesterone
b) Medroxyprogesterone acetate
c) Norethindrone
d) Levonorgestrel
a) Micronized progesterone
Rationale: Micronized progesterone has a more favorable cardiovascular risk profile than
synthetic progestins (NAMS, 2025)._
5. What is the absolute contraindication for hormone therapy?
a) Age over 60
b) History of breast cancer
c) Hot flashes
d) Vaginal dryness
b) History of breast cancer
Rationale: HT is contraindicated in breast cancer survivors due to increased recurrence risk
(NAMS, 2025)._
6. Which estrogen formulation is recommended for genitourinary
syndrome of menopause?
a) Oral conjugated estrogens
b) Low-dose vaginal estrogen
c) Transdermal estradiol
d) High-dose estrogen patch
b) Low-dose vaginal estrogen
Rationale: Low-dose vaginal estrogen is first-line for GSM, with minimal systemic absorption
(NAMS GSM Protocol, 2025)._
7. What is the primary risk of hormone therapy in women over age 60?
a) Venous thromboembolism
b) Stroke
c) Breast cancer
d) All of the above
d) All of the above
Rationale: HT in older women increases risks of VTE, stroke, and breast cancer, requiring
individualized assessment (NAMS, 2025)._
8. Which non-hormonal therapy is recommended for vasomotor
symptoms?
a) Paroxetine
b) Gabapentin
c) Both a and b
, d) Neither a nor b
c) Both a and b
Rationale: SSRIs like paroxetine and gabapentinoids like gabapentin are effective
non-hormonal options for hot flashes (NAMS, 2025)._
9. What is the recommended screening for breast cancer in women on HT?
a) Annual mammogram
b) Biennial mammogram
c) No screening needed
d) Monthly self-exam only
a) Annual mammogram
Rationale: Women on HT require annual mammograms for breast cancer screening, starting at
age 40 or earlier if high risk (USPSTF, 2025)._
10. Which hormone therapy regimen is recommended for a woman with a
uterus?
a) Estrogen only
b) Estrogen plus progestogen
c) Progestogen only
d) No hormone therapy
b) Estrogen plus progestogen
Rationale: Combined estrogen-progestogen therapy is required in women with an intact uterus
to prevent endometrial hyperplasia (NAMS, 2025)._
11. What is the primary benefit of transdermal hormone therapy?
a) Lower cost
b) Reduced first-pass liver metabolism
c) Easier administration
d) Longer duration of action
b) Reduced first-pass liver metabolism
Rationale: Transdermal HT bypasses first-pass metabolism, lowering VTE risk (NAMS, 2025)._
12. Which symptom is most indicative of genitourinary syndrome of
menopause?
a) Hot flashes
b) Vaginal dryness
c) Mood swings
d) Weight gain
b) Vaginal dryness
Rationale: GSM is characterized by vaginal dryness, dyspareunia, and urinary symptoms due to
estrogen deficiency (NAMS GSM Protocol, 2025)._
13. What is the recommended starting dose for estradiol vaginal ring?
a) 0.05 mg/day
b) 0.1 mg/day
c) 0.3 mg/day
